| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/JC.2007-2249 |
| P8608 | Fatcat ID | release_3og3nz6nrvhjbpotdswoqfsn4e |
| P698 | PubMed publication ID | 18285411 |
| P50 | author | Dorte Glintborg | Q39184448 |
| Marianne Andersen | Q42482144 | ||
| Anne Pernille Hermann | Q116782498 | ||
| P2093 | author name string | Lene Heickendorff | |
| Claus Hagen | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| patient | Q181600 | ||
| placebo | Q269829 | ||
| polycystic ovary | Q5547896 | ||
| polycystic ovary syndrome | Q500816 | ||
| P304 | page(s) | 1696-1701 | |
| P577 | publication date | 2008-02-19 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial | |
| P478 | volume | 93 |
| Q37942705 | An old friend in a new light: the role of osteocalcin in energy metabolism |
| Q37689166 | An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome |
| Q43174291 | Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus |
| Q45947423 | Bone disease, gestational diabetes mellitus, and health care. |
| Q37767428 | Bone loss and fracture risk associated with thiazolidinedione therapy. |
| Q34161200 | Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis |
| Q59315870 | Bone mineral density and vitamin D in PCOS and hirsutism |
| Q34577452 | Bone mineral density in women with polycystic ovary syndrome |
| Q37161933 | Cardiometabolic interventions - focus on transcriptional regulators |
| Q35964678 | Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins |
| Q64259048 | Cooperative impact of thiazolidinedione and fatty acid synthase on human osteogenesis |
| Q38999214 | Diabetes Drug Effects on the Skeleton. |
| Q37857043 | Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures |
| Q37798059 | Diabetes and skeletal health |
| Q38092275 | Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? |
| Q26775763 | Drugs for type 2 diabetes: role in the regulation of bone metabolism |
| Q55417016 | Effect of Hexadecyl Azelaoyl Phosphatidylcholine on Cardiomyocyte Apoptosis in Myocardial Ischemia-Reperfusion Injury: A Hypothesis. |
| Q36433551 | Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study |
| Q41656785 | Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats |
| Q33792658 | Effects of vitamin D combined with pioglitazone hydrochloride on bone mineral density and bone metabolism in Type 2 diabetic nephropathy |
| Q40350366 | Fracture Risk Is Decreased in Women With Polycystic Ovary Syndrome: A Register-Based and Population-Based Cohort Study |
| Q37511845 | Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences |
| Q33552875 | Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function |
| Q37270218 | Impact of conjugated linoleic acid on bone physiology: proposed mechanism involving inhibition of adipogenesis |
| Q36807306 | Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia |
| Q24655666 | Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis |
| Q47105302 | Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study |
| Q26798968 | Management of endocrine disease: Diabetes and osteoporosis: cause for concern? |
| Q26829098 | Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects |
| Q38441017 | Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review |
| Q38856983 | PPARγ signaling and emerging opportunities for improved therapeutics |
| Q35998796 | Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications. |
| Q36217472 | Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial |
| Q36139056 | Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review |
| Q37776510 | Pioglitazone: beyond glucose control. |
| Q39508482 | Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome. |
| Q37167551 | Redefining the role of thiazolidinediones in the management of type 2 diabetes |
| Q34620706 | Risk management in the treatment of type 2 diabetes with pioglitazone |
| Q30611122 | Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. |
| Q35949113 | Risk of fracture with thiazolidinediones: disease or drugs? |
| Q37520986 | Risk of fractures with glitazones: a critical review of the evidence to date |
| Q37202144 | Safety and efficacy of rosiglitazone in the elderly diabetic patient |
| Q36716222 | Safety of Anti-Diabetic Therapies on Bone |
| Q84700522 | Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome |
| Q36868437 | TZDs and Bone: A Review of the Recent Clinical Evidence |
| Q46807429 | The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate |
| Q38537377 | The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis |
| Q36969616 | The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes. |
| Q37457675 | The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis |
| Q37848841 | The safety of thiazolidinediones |
| Q38322718 | The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q38901674 | Thiazolidinediones Inhibit Mouse Osteoblastic MC3T3-E1 Cell Proliferation in Part Through the Wnt Signaling Pathway |
| Q37889370 | Thiazolidinediones and fracture risk in patients with Type 2 diabetes |
| Q36078767 | Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. |
| Q37763184 | Thiazolinedione treatment in PCOS--an update |
| Q43436806 | Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? |
| Q87674168 | [Pharmacogenic osteoporosis beyond cortisone. Proton pump inhibitors, glitazones and diuretics] |
Search more.